Neonatal bacterial meningitis

Seminars in Neonatology

Volumn 6, Issue 2, 2001, Pages 157-172

  Polin, Richard A ^a   Harris, Mary C ^b  

^a Columbia University ^*  (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Bacterial neurotropism; Blood brain barrier; Brain injury; Chemokines; Cytokines

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; BETA LACTAM ANTIBIOTIC; CEFOTAXIME; CEPHALOSPORIN DERIVATIVE; CORTICOSTEROID; GENTAMICIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; VANCOMYCIN;

ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL MENINGITIS; HIGH RISK POPULATION; HUMAN; IMMUNE RESPONSE; INFLAMMATION; NEUROLOGIC DISEASE; NEWBORN; NEWBORN INFECTION; NEWBORN INTENSIVE CARE; NEWBORN MORBIDITY; NEWBORN MORTALITY; PATHOPHYSIOLOGY; RISK FACTOR;

EID: 0034900277     PISSN: 10842756     EISSN: None     Source Type: Journal    
DOI: 10.1053/siny.2001.0045     Document Type: Article

References (102)

1. The results of the serum treatment in thirteen hundred cases of epidemic meningitis
2. Sulfonamides and meningitis
3. Bacterial meningitis in the newborn: A prospective study of mortality and morbidity
4. Predicting the outcome of neonatal bacterial meningitis
5. Bacterial meningitis and the newborn infant
6. Bacterial sepsis and meningitis
7. Early-onset group B streptococcal sepsis: A current assessment
8. Group B streptococcus
9. Risk factors for early-onset group B streptococcal sepsis: Estimation of odds ratios by critical literature review
10. Suppurative meningitis due to streptococci of lancefield group B: A study of 33 infants
11. Increased cell adherence of group b streptococci from preterm infants with neonatal sepsis
12. Bacterial meningitis in the United States in 1995
13. Bacterial meningitis in neonates and children
14. Fifteen years of experience with bacterial meningitis
15. Infections of the central nervous system in the newborn
16. Prophylaxis for neonatal group B streptococcal infection
17. Epidermiology of Escherichia coli K1 in healthy and diseased newborns
18. Relation between Escherichia coli K1 capsular polysaccharide and clinical outcome in neonatal meningitis
19. Virulence patterns of Escherichia coli and K1 strains associated with neonatal meningitis
20. Bacterial and fungal intracranial infections
21. Pseudomonas aeruginosa infection in very low birth weight infants: A case control study
22. Cerebrospinal fluid examination in symptom-free infants with risk factors for infection
23. The role of the lumbar puncture in the admission sepsis evaluation of the premature infant
24. Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis
25. Lumbar puncture in the evaluation of suspected neonatal sepsis
26. No lumbar puncture in the evaluation for early neonatal sepsis: Will meningitis be missed?
27. Evaluation of routine lumbar puncture in newborn infants with respiratory distress
28. Meningitis in premature infants with respiratory distress: Role of admission lumbar puncture
29. Lumbar puncture frequency and cerebrospinal fluid analysis in the neonate
30. Term newborns who are at risk for sepsis: Are lumbar punctures necessary?
31. Cerebrospinal fluid evaluation in neonates: Comparison of high-risk infants with and without meningitis
32. Report of the task force on diagnosis and management of meningitis
33. Cerebrospinal fluid values in the term neonate
34. Listeria meningitis in infants and children
35. Cytokines and the inflammatory response
36. Roles of pro-inflammatory and anti-inflammatory cytokines in pathophysiology of bacterial meningitis and effect of adjunctive therapy
37. Cytokines and chemokines in meningeal inflammation: Biology and clinical implications
38. High levels of interleukin 10 and tumor necrosis factor a in cerebrospinal fluid during the onset of bacterial meningitis
39. Levels of transforming growth factor, tumor necrosis factor α, and interleukin 6 in cerebrospinal fluid: Association with clinical outcome for children with bacterial meningitis
40. Cytokine elevations in infants with bacterial and aseptic meningitis
41. Cerebrospinal fluid interleukin 1-beta and tumor necrosis factor concentrations and outcome from neonatal gram-negative enteric bacillary meningitis
42. Cerebrospinal fluid prostaglandins, interleukin-1, and tumor necrosis factor in bacterial meningitis, clinical and laboratory correlations in placebo-treated and dexamethasonetreated patients
43. Interleukin 6 activity in infants and children with bacterial meningitis
44. Anti-interleukin-8 auto-antibodies in cerebrospinal fluid of children with purulent meningitis
45. Chemokine profiles in the cerebrospinal fluid (CSF) during the course of pyogenic and tuberculous meningitis
46. Cerebrospinal fluid interleukin-6, interleukin-8, and tumor necrosis factor-α in children with central nervous system infections
47. Bacterial meningitis: Pathogenesis, pathophysiology, and progress
48. Pathogenesis of bacterial meningitis
49. Pathogenetic events during infection of the human Nasopharynx with Neisseria meningitidis and Haemophilus influenzae
50. The K1 capsule is the critical determinant in the development of Escherichia coli meningitis in the rat
51. Binding characteristics of S fimbriated Escherichia coli to isolated brain microvascular endothelial cells
52. Cytokines and chemokines in meningeal inflammation: Biology and clinical implications
53. Matrix metalloproteinases contribute to the blood-brain barrier disruption during bacterial meningitis
54. Differential expression of matrix metalloproteinases in bacterial meningitis
55. Adhesion molecules - Their role in health and disease
56. Mechanisms of brain injury in bacterial meningitis: Workshop summary
57. Molecular mechanisms of brain damage in bacterial meningitis
58. Cerebral arteritis and phlebitis in pneumococcal meningitis
59. Morphologic alterations of the blood-brain barrier with experimental meningitis in the rat
60. The syndrome of inappropriate secretion of antidiuretic hormone in children with bacterial meningitis
61. Cerebrospinal fluid outflow resistance in rabbits with experimental meningitis, alterations with Penicillin and Methylprednisolone
62. Experimental pneumococcal meningitis: Cerebrovascular alterations, brain edema, and meningeal inflammation are linked to the production of nitric oxide
63. Regional cerebral blood flow, cerebral metabolic rate of oxygen, and cerebrospinal fluid acid-base variables in patients with acute meningitis and with acute encephalitis
64. Bacterial meningitis in infancy: Effects on intracraanial pressure and cerebral blood flow velocity
65. Abnormalities of cerebral blood flow in the acute phase of bacterial meningitis in adults
66. Endothelin inhibition improves cerebral blood flow and is neuroprotective in pneumococcal meningitis
67. Tumor necrosis factor-α contributes to apoptosis in hippocampal neurons during experimental group B Streptococcal meningitis
68. Measurement of levels of tumor necrosis factor-alpha and interleukin-1 beta in the CSF of patients with meningitis of different etilogies: Utility in the differential diagnosis
69. L-10 inhibits cytokine production by activated macrophages
70. Interleukin-10 (IL-10) inhibits the induction of nitric oxide synthase by interferon-gamma in murine macrophages
71. Potential role of nitric oxide in the pathophysiology of experimental bacterial meningitis in rats
72. Inducible nitric oxide synthase and the effect of aminoguanidine in experimental neonatal meningitis
73. Effect of recombinant human tumor necrosis factor-alpha on cerebral oxygen uptake, cerebrospinal fluid lactate, and cerebral blood flow in the rabbit: Role of nitric oxide
74. Modulation of cytokine production by transforming growth factor-beta
75. Transforming growth factor beta downregulates interleukin-1 (IL-1)-induced IL-6 production by human monocytes
76. Inhibition of cytokine production by cyclosporin A and transforming growth factor beta
77. Apparent hydroxyl radical production by peroxynitrite: Implications for endothelial injury from nitric oxide and superoxide
78. Neuronal injury in meningitis
79. Nitric oxide in septic and aseptic meningitis in children
80. Amino acids in cerebrospinal and brain interstitial fluid in experimental Pneumococcal meningitis
81. Neuroprotective effect of excitatory amino acid antagonist Kynurenic Scid in experimental bacterial meningitis
82. Efficacy of anti-tumor necrosis factor-alpha antibody as an adjunctive therapy in experimental Escherichia coli meningitis in the newborn piglet
83. The efficacy of pentoxifylline as an anti-inflammatory agent in experimental Escherichia coli meningitis in the newborn piglet
84. The efficacy of α-Phenyl-N-tert-Butylnitrone on brain cell membrane function and energy metabolism in experimental Escherichia coli meningitis in the newborn piglet
85. Antibiotic pharmacodynamics in cerebrospinal fluid
86. Transporting therapeutics across the blood-brain barrier
87. Comparative distribution of Quinolone antibiotics in cerebrospinal fluid and brain in rats and dogs
88. Rationale for clinical trials evaluating Ceftriaxone in the therapy of bacterial meningitis
89. Ceftriaxone pharmacokinetics in the central nervous system
90. Advance in understanding the pharmacology of agents used to treat bacterial meningitis
91. Pharmacokinetics and bacteriological efficacy of Cefoperazone, Ceftriaxone, and Moxalactam in experimental Streptococcus pneumoniae and Haemophilus influenzae meningitis
92. Pharmacokinetics and bacteriological efficacy of mezlocillin in experimental E. Coli and Listeria monocytogenes meningitis
93. Treatment of bacterial meningitis
94. Lack of effectiveness of dexamethasone in neonatal bacterial meningitis
95. Meningitis in the newborn - A 14 year review
96. Long-term outcome of neonatal meningitis
97. Long-term sequelae of group b streptococcal meningitis in infants
98. Gram-negative enteric bacillary meningitis: A twenty-one-year experience
99. Neonatal gram-negative meningitis: A 10 year review with reference to outcome and relapse of infection
100. Prognostic value of EEG in neonatal meningitis: Retrospective study of 29 infants